Stay updated on Pembrolizumab with Radiotherapy in CTCL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Radiotherapy in CTCL Clinical Trial page.

Latest updates to the Pembrolizumab with Radiotherapy in CTCL Clinical Trial page
- Check7 days agoChange DetectedThe page footer now shows Revision: v3.6.3, indicating a platform update that affects the interface but not the clinical trial details.SummaryDifference0.0%

- Check14 days agoChange DetectedThe page shows a revision stamp update from v3.6.0 to v3.6.2, indicating a small deployment update.SummaryDifference0.0%

- Check21 days agoChange DetectedDeleted items remove the drug Pembrolizumab and several lymphoma-related disease terms from the page, altering the study's described intervention and target conditions. These removals also affect how the study is indexed and understood by users seeking details about treatment and eligibility.SummaryDifference18%

- Check28 days agoChange DetectedRecruitment status now shows no further participant enrollment, and new help/navigation sections are added along with a revision update to v3.6.0; the old label formatting and prior revision tag were removed.SummaryDifference0.4%

- Check35 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a new build. There are no changes to study details or visible content.SummaryDifference0.0%

- Check57 days agoChange DetectedThe page's revision metadata now shows Revision: v3.5.4, replacing the previous Revision: v3.5.3. This is an administrative update to the page versioning rather than a change to trial data or details.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab with Radiotherapy in CTCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Radiotherapy in CTCL Clinical Trial page.